Table 3.
Comparison of preclinical Alzheimer's disease neuroimaging modalities.
| Neuroimaging modalities | Differences | References |
|---|---|---|
| Tau-18F-T807-PET vs. 13C-PIB-PET | Region specific distribution of tau deposition | Johnson et al., 2016 |
| Tau-18F-THK5317-PET vs. 18FDG-PET | Progression of AD is better tracked by 18FDG-PET | Chiotis et al., 2017 |
| 18FDG-PET vs. DTI with sMRI | Whole-brain white matter network properties in preclinical AD can be detected by DTI with sMRI before structural markers of significant neurodegeneration such as atrophy (by MRI) or reduced cortical glucose utilization (by 18FDG-PET) | Fischer et al., 2015 |
| 18FDG-PET vs. ASL\MRI | ASL MRI is not invasive 18FDG-PET is more expensive than ASL/MRI ASL/MRI operation is simple |
Wolk and Detre, 2012 |
Aβ, amyloid beta; AD, Alzheimer's disease; ASL MRI, arterial spin-labeled magnetic resonance imaging; DTI, diffusion tensor imaging; FDG, fluoro-2-deoxy-D-glucose; fMRI, functional MRI; 18F-T807-PET, Fluorinated tau PET ligand; Tau-18F-THK5317, Fluorinated tau PET ligand; MRI, magnetic resonance imaging; PET, positron emission tomography; PIB, Pittsburgh compound B.